Lilly's revenue gains have helped its stock to roar higher.Eli Lilly (LLY -3.36%) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro and Zepbound. Together, these drugs are adding billions of dollars to the company's top line, helping Lilly report double-digit gains in quarterly revenue.Today Eli Lilly shares the market with rival Novo Nordisk, which sells two weight loss drugs that wor ...